edaravone has been researched along with Ischemia in 16 studies
Ischemia: A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study aimed to investigate the influences of edaravone on necroptosis-related proteins and oxidative stress in rats with lower extremity ischemia/reperfusion (I/R) injury." | 8.12 | Influences of Edaravone on Necroptosis-Related Proteins and Oxidative Stress in Rats with Lower Extremity Ischemia/Reperfusion Injury. ( Hu, Z; Li, Y; Wang, L; Zhao, G; Zhao, L, 2022) |
| " Edaravone is a powerful free radical scavenger used for the treatment of ischemia/reperfusion diseases due to its anti-oxidative stress and anti-inflammatory properties." | 8.02 | Effect of edaravone on pregnant mice and their developing fetuses subjected to placental ischemia. ( Abe, K; Atallah, M; Yamashita, T, 2021) |
| "A novel free radical scavenger, edaravone, has been demonstrated to exert a neuroprotective effect and improve outcomes in acute ischemic stroke, but there have been few clinical studies." | 7.79 | Investigation of effect of edaravone on ischemic stroke. ( Adachi, H; Ishibashi, A; Yoshitake, Y, 2013) |
| "The protective effect of edaravone, an inhibitor of reactive oxygen species (ROS), against the development of ischemia-induced facial palsy was investigated." | 7.74 | Protective effects of edaravone against ischemia-induced facial palsy. ( Hamada, M; Kakigi, A; Nakatani, H; Okada, T; Takeda, S; Takeda, T; Takumida, M; Yamakawa, K, 2008) |
| " However, poor water solubility, low stability, and bioavailability in aqueous media are major EDV drawbacks." | 5.91 | Enhancing the Neuroprotection Potential of Edaravone in Transient Global Ischemia Treatment with Glutathione- (GSH-) Conjugated Poly(methacrylic acid) Nanogel as a Promising Carrier for Targeted Brain Drug Delivery. ( Bijani, S; Danafar, H; Hosseini, MJ; Islambulchilar, Z; Kalantari-Hesari, A; Mozafari, F; Ramazani, A; Rashidzadeh, H; Zare-Molaei, F, 2023) |
| "Edaravone treatment decreased the neutrophil infiltration, the lipid membrane peroxidation, and the expression of proinflammatory cytokine interleukin-6 mRNA in the lungs after intestinal I/R compared to the I/R-treated rat lungs without edaravone treatment." | 5.33 | Edaravone protects against lung injury induced by intestinal ischemia/reperfusion in rat. ( Horikawa, S; Ito, K; Ozasa, H, 2005) |
| "The study aimed to investigate the influences of edaravone on necroptosis-related proteins and oxidative stress in rats with lower extremity ischemia/reperfusion (I/R) injury." | 4.12 | Influences of Edaravone on Necroptosis-Related Proteins and Oxidative Stress in Rats with Lower Extremity Ischemia/Reperfusion Injury. ( Hu, Z; Li, Y; Wang, L; Zhao, G; Zhao, L, 2022) |
| " Edaravone is a powerful free radical scavenger used for the treatment of ischemia/reperfusion diseases due to its anti-oxidative stress and anti-inflammatory properties." | 4.02 | Effect of edaravone on pregnant mice and their developing fetuses subjected to placental ischemia. ( Abe, K; Atallah, M; Yamashita, T, 2021) |
| "A novel free radical scavenger, edaravone, has been demonstrated to exert a neuroprotective effect and improve outcomes in acute ischemic stroke, but there have been few clinical studies." | 3.79 | Investigation of effect of edaravone on ischemic stroke. ( Adachi, H; Ishibashi, A; Yoshitake, Y, 2013) |
| "The protective effect of edaravone, an inhibitor of reactive oxygen species (ROS), against the development of ischemia-induced facial palsy was investigated." | 3.74 | Protective effects of edaravone against ischemia-induced facial palsy. ( Hamada, M; Kakigi, A; Nakatani, H; Okada, T; Takeda, S; Takeda, T; Takumida, M; Yamakawa, K, 2008) |
| " However, poor water solubility, low stability, and bioavailability in aqueous media are major EDV drawbacks." | 1.91 | Enhancing the Neuroprotection Potential of Edaravone in Transient Global Ischemia Treatment with Glutathione- (GSH-) Conjugated Poly(methacrylic acid) Nanogel as a Promising Carrier for Targeted Brain Drug Delivery. ( Bijani, S; Danafar, H; Hosseini, MJ; Islambulchilar, Z; Kalantari-Hesari, A; Mozafari, F; Ramazani, A; Rashidzadeh, H; Zare-Molaei, F, 2023) |
| "Edaravone treatment decreased the neutrophil infiltration, the lipid membrane peroxidation, and the expression of proinflammatory cytokine interleukin-6 mRNA in the lungs after intestinal I/R compared to the I/R-treated rat lungs without edaravone treatment." | 1.33 | Edaravone protects against lung injury induced by intestinal ischemia/reperfusion in rat. ( Horikawa, S; Ito, K; Ozasa, H, 2005) |
| "Cochlear ischemia was induced in the animals by occluding the vertebral arteries bilaterally for 15 min." | 1.32 | Free radical scavenger protects against inner hair cell loss after cochlear ischemia. ( Gyo, K; Hakuba, N; Hyodo, J; Maetani, T; Shimizu, Y; Taniguchi, M, 2003) |
| "Paraplegia is a serious complication of operations on the thoracic and thoracoabdominal aorta." | 1.32 | MCI-186 reduces oxidative cellular damage and increases DNA repair function in the rabbit spinal cord after transient ischemia. ( Abe, K; Itoyama, Y; Sakurai, M; Tabayashi, K; Takahashi, G, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (62.50) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 4 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, G | 2 |
| Zhao, L | 2 |
| Li, Y | 2 |
| Wang, L | 2 |
| Hu, Z | 2 |
| Mozafari, F | 1 |
| Rashidzadeh, H | 1 |
| Bijani, S | 1 |
| Zare-Molaei, F | 1 |
| Islambulchilar, Z | 1 |
| Danafar, H | 1 |
| Kalantari-Hesari, A | 1 |
| Ramazani, A | 1 |
| Hosseini, MJ | 1 |
| Yamato, SH | 1 |
| Nakamura, S | 1 |
| Htun, Y | 1 |
| Nakamura, M | 1 |
| Jinnai, W | 1 |
| Nakao, Y | 1 |
| Mitsuie, T | 1 |
| Koyano, K | 1 |
| Wakabayashi, T | 1 |
| Morimoto, AH | 1 |
| Sugino, M | 1 |
| Iwase, T | 1 |
| Kondo, SI | 1 |
| Yasuda, S | 1 |
| Ueno, M | 1 |
| Miki, T | 1 |
| Kusaka, T | 1 |
| Atallah, M | 1 |
| Yamashita, T | 1 |
| Abe, K | 3 |
| Ishibashi, A | 1 |
| Yoshitake, Y | 1 |
| Adachi, H | 1 |
| Chiazza, F | 1 |
| Chegaev, K | 1 |
| Rogazzo, M | 1 |
| Cutrin, JC | 1 |
| Benetti, E | 1 |
| Lazzarato, L | 1 |
| Fruttero, R | 1 |
| Collino, M | 1 |
| Ninomiya, M | 1 |
| Shimada, M | 1 |
| Harada, N | 1 |
| Shiotani, S | 1 |
| Hiroshige, S | 1 |
| Soejima, Y | 1 |
| Suehiro, T | 1 |
| Sugimachi, K | 1 |
| Maetani, T | 1 |
| Hakuba, N | 1 |
| Taniguchi, M | 1 |
| Hyodo, J | 1 |
| Shimizu, Y | 1 |
| Gyo, K | 1 |
| Takahashi, G | 2 |
| Sakurai, M | 2 |
| Itoyama, Y | 2 |
| Tabayashi, K | 2 |
| Qi, X | 1 |
| Okuma, Y | 1 |
| Hosoi, T | 1 |
| Nomura, Y | 1 |
| Ito, K | 1 |
| Ozasa, H | 1 |
| Horikawa, S | 1 |
| Hashizume, K | 1 |
| Ueda, T | 1 |
| Shimizu, H | 1 |
| Mori, A | 1 |
| Yozu, R | 1 |
| Song, Y | 1 |
| Li, M | 1 |
| Li, JC | 1 |
| Wei, EQ | 1 |
| Satoh, S | 1 |
| Toshima, Y | 1 |
| Ikegaki, I | 1 |
| Iwasaki, M | 1 |
| Asano, T | 1 |
| Takeda, T | 1 |
| Takeda, S | 1 |
| Takumida, M | 1 |
| Okada, T | 1 |
| Kakigi, A | 1 |
| Nakatani, H | 1 |
| Hamada, M | 1 |
| Yamakawa, K | 1 |
16 other studies available for edaravone and Ischemia
| Article | Year |
|---|---|
Influences of Edaravone on Necroptosis-Related Proteins and Oxidative Stress in Rats with Lower Extremity Ischemia/Reperfusion Injury.
Topics: Animals; Apoptosis; Disease Models, Animal; Edaravone; Interleukin-6; Ischemia; Oxidative Stress; Ra | 2022 |
Influences of Edaravone on Necroptosis-Related Proteins and Oxidative Stress in Rats with Lower Extremity Ischemia/Reperfusion Injury.
Topics: Animals; Apoptosis; Disease Models, Animal; Edaravone; Interleukin-6; Ischemia; Oxidative Stress; Ra | 2022 |
Influences of Edaravone on Necroptosis-Related Proteins and Oxidative Stress in Rats with Lower Extremity Ischemia/Reperfusion Injury.
Topics: Animals; Apoptosis; Disease Models, Animal; Edaravone; Interleukin-6; Ischemia; Oxidative Stress; Ra | 2022 |
Influences of Edaravone on Necroptosis-Related Proteins and Oxidative Stress in Rats with Lower Extremity Ischemia/Reperfusion Injury.
Topics: Animals; Apoptosis; Disease Models, Animal; Edaravone; Interleukin-6; Ischemia; Oxidative Stress; Ra | 2022 |
Enhancing the Neuroprotection Potential of Edaravone in Transient Global Ischemia Treatment with Glutathione- (GSH-) Conjugated Poly(methacrylic acid) Nanogel as a Promising Carrier for Targeted Brain Drug Delivery.
Topics: Acute Disease; Animals; Antioxidants; Brain; Edaravone; Glutathione; Ischemia; Ischemic Stroke; Nano | 2023 |
Intravenous Edaravone plus Therapeutic Hypothermia Offers Limited Neuroprotection in the Hypoxic-Ischaemic Newborn Piglet.
Topics: Animals; Animals, Newborn; Brain; Disease Models, Animal; Edaravone; Hypothermia, Induced; Hypoxia; | 2020 |
Effect of edaravone on pregnant mice and their developing fetuses subjected to placental ischemia.
Topics: Animals; Disease Models, Animal; Edaravone; Female; Ischemia; Male; Mice; Mice, Inbred C57BL; Oxidat | 2021 |
Investigation of effect of edaravone on ischemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Antipyrine; Arginine; Edaravone; Female; Free Radical Scavengers; Hu | 2013 |
A nitric oxide-donor furoxan moiety improves the efficacy of edaravone against early renal dysfunction and injury evoked by ischemia/reperfusion.
Topics: Acetylglucosamine; Acute-Phase Proteins; Animals; Antipyrine; Creatinine; Disease Models, Animal; Ed | 2015 |
Beneficial effect of MCI-186 on hepatic warm ischemia-reperfusion in the rat.
Topics: Animals; Antipyrine; Apoptosis; Edaravone; Free Radical Scavengers; In Situ Nick-End Labeling; Ische | 2002 |
Free radical scavenger protects against inner hair cell loss after cochlear ischemia.
Topics: Analysis of Variance; Animals; Antipyrine; Auditory Threshold; Cell Death; Cochlear Diseases; Edarav | 2003 |
MCI-186 prevents spinal cord damage and affects enzyme levels of nitric oxide synthase and Cu/Zn superoxide dismutase after transient ischemia in rabbits.
Topics: Animals; Antipyrine; Biopsy, Needle; Disease Models, Animal; Edaravone; Immunohistochemistry; Inject | 2003 |
Edaravone protects against hypoxia/ischemia-induced endoplasmic reticulum dysfunction.
Topics: Animals; Antipyrine; Apoptosis; Brain Ischemia; Cells, Cultured; Edaravone; Endoplasmic Reticulum; F | 2004 |
MCI-186 reduces oxidative cellular damage and increases DNA repair function in the rabbit spinal cord after transient ischemia.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antipyrine; Apoptosis; Ataxia; Biomarkers; Cell Count; Cell Nu | 2004 |
Edaravone protects against lung injury induced by intestinal ischemia/reperfusion in rat.
Topics: Animals; Antipyrine; Disease Progression; Edaravone; Interleukin-6; Intestines; Ischemia; Lung; Male | 2005 |
Effect of the free radical scavenger MCI-186 on spinal cord reperfusion after transient ischemia in the rabbit.
Topics: Animals; Antipyrine; Cell Death; Dose-Response Relationship, Drug; Edaravone; Free Radical Scavenger | 2005 |
Edaravone protects PC12 cells from ischemic-like injury via attenuating the damage to mitochondria.
Topics: Animals; Antipyrine; Apoptosis; bcl-2-Associated X Protein; Edaravone; Flow Cytometry; Ischemia; Mic | 2006 |
Wide therapeutic time window for fasudil neuroprotection against ischemia-induced delayed neuronal death in gerbils.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antipyrine; Cell Death; Dose-Response Relati | 2007 |
Protective effects of edaravone against ischemia-induced facial palsy.
Topics: Animals; Antipyrine; Axons; Blinking; Edaravone; Facial Nerve; Facial Paralysis; Free Radical Scaven | 2008 |